<DOC>
	<DOCNO>NCT00429182</DOCNO>
	<brief_summary>The goal clinical research study learn relationship high-dose chemotherapy ( HDCT ) circulate tumor cell ( CTCs ) control metastatic breast cancer . The study also investigate role CTCs breast cancer .</brief_summary>
	<brief_title>Purged Circulating Tumor Cells ( CTCs ) From Metastatic Breast Cancer</brief_title>
	<detailed_description>Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Carboplatin thiotepa design interfere growth cancer cell stop cell division , may cause cell die . Mesna design prevent toxicity cyclophosphamide . Granulocyte colony-stimulating factor ( G-CSF GCSF ) design help white blood count recover transplant . If find eligible take part study , give G-CSF twice day needle skin ( subcutaneous injection ) , Days 1-5 . On Day 5 , stem cell collection begin . You catheter place vein chest . A central venous catheter sterile flexible tube place large vein local anesthesia . Your physician explain procedure detail , require sign separate consent form procedure . If shrinkage tumor need , doctor may use chemotherapy combine G-CSF described . Your doctor explain procedure detail , ask sign separate consent form procedure . Blood remove body catheter pass machine separate stem cell cell . The stem cell frozen storage , blood return body . This 3-hour process call apheresis . The process do day 1-6 day enough stem cell collect . Blood ( 4 teaspoon ) collect first Apheresis comparison sample check breast cancer leftover blood . The collected blood cell go filter select blood stem cell CTCs leave behind . Blood ( 2 tablespoon ) draw daily peripheral blood stem cell collection . On Days 6 , 5 , 4 , 3 transplant , receive cyclophosphamide , mesna , thiotepa , carboplatin needle vein . Blood ( 2 teaspoon ) draw routine test . On Day 0 , stem cell transplant . Stem cell go device remove breast cancer cell . If bone marrow collect enough stem cell , researcher treat bone marrow remove breast cancer cell . Collected breast cancer cell study understand biological role cancer cell . After transplant , G-CSF give needle skin white blood cell count normal 3 day row . Blood ( 2 tablespoon ) draw daily transplant still hospital . You expect remain hospital 3 week . Once release hospital , blood ( 2 tablespoon ) draw routine test every week cell count recover . Five ( 5 ) week transplant , doctor think need , radiation therapy , hormonal therapy , receive trastuzumab . At Months 1 , 3 , 6 , 9 , 12 , 16 , 20 , 24 transplant , complete medical history record , physical exam . You chest X-ray bone scan . If doctor think need , x-ray hot spot area show positive bone scan . If doctor think need , may CT scan head , mammogram , breast ultrasound perform . At Months 1 3 transplant , PET/CT scan . At Months 6 , 9 , 12 , 16 , 20 , 24 transplant , CT scan chest abdomen need check status disease . Blood ( 2 teaspoon ) draw measure cancer marker CTCs . While study must notify doctor new drug take . This investigational study . The transplant FDA approve . The drug G-CSF , cyclophosphamide , carboplatin , thiotepa approve FDA commercially available . The CliniMACS device commercially available FDA approve . The CliniMACS device use research provide free charge . Up 70 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . 18 55 year old 2 . Metastatic breast carcinoma . 3 . Histological confirmation invasive breast carcinoma 4 . Complete partial response pretransplant standarddose chemotherapy , hormonal therapy . For bone disease , stable disease ( SD ) allow . 5 . Patient must tumor assessed estrogenreceptor ( ER ) progesteronereceptor ( PR ) . 6 . Persistent detectable nondetectable CTCs Veridex Technology completion standard therapy . 7 . Zubrod performance status 0 1 . 8 . Patients must adequate hematological parameter ( White Blood Count/WBC &gt; = 3,000/mm3 ; platelet count &gt; = 100,000/mm3 ) 9 . Adequate renal function ( serum creatinine &lt; = 1.5mg/dl ) 10 . Adequate liver function ( total bilirubin , serum glutamate pyruvate transaminase ( SGPT ) &lt; = 2 time normal ) . 11 . Adequate cardiac function ( Left ventricular ejection fraction ( LVEF ) &gt; = 50 % ) . 12 . Adequate pulmonary function ( Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; = 50 % predict value ) . 13 . Females childbearing ( woman postmenopausal &lt; 1 year , surgically sterilize , abstinent ) potential must use adequate contraception . 14 . Patients must sign informed consent . 1 . Prior HDCT Autologous hematopoietic stem cell transplantation ( AHST ) adjuvant set . 2 . History presence brain/leptomeningeal metastasis . 3 . History malignancy except cured nonmelanoma skin cancer cure cervical carcinoma situ . 4 . Presence severe medical illness condition . Severe heart disease , ( myocardial ischemia , myocardial infarction , etc . ) Pulmonary disease ( COPD , asthma , etc ) . Renal failure hepatic failure . 5 . Clinically significant active infection ( patient require IV antibiotic , uncontrolled infection , hospitalize due infection ) . 6 . HIV infection . 7 . Pregnant lactating woman . 8 . Medical , social psychologic factor would prevent patient receive cooperate full course therapy understanding informed consent procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>breast carcinoma</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Neosar</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Purged Autologous Stem Cells</keyword>
	<keyword>Circulating Tumor Cells</keyword>
	<keyword>CTCs</keyword>
</DOC>